SMYD3 and breast carcinoma: Likewise, a separate study indicated that a SYMD3 inhibitor, inhibitor-4, demonstrated potent impacts on two breast cancer lines, MCF7 and MDA-MB-231 (both lines linked to overexpression of SMYD3) [29].